James P. Ohr
Expertise in
23
conditions

Dr. James P. Ohr

Hematology Oncology
2500 West 12th Street, 
Erie, PA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
23
conditions
2500 West 12th Street, 
Erie, PA 

Overview

James P. Ohr, DO, is a medical oncologist and hematologist at UPMC Hillman Cancer Center. He has a clinical interest in gastrointestinal malignancies, peritoneal carcinomas, and head and neck malignancies.

Dr. Ohr is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Throat Cancer, Laryngeal Cancer, Pleuropulmonary Blastoma, Oral Squamous Cell Carcinoma, and Gastrostomy.

Dr. Ohr is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 42 peer reviewed articles and participating in 12 clinical trials. Dr. Ohr is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in PA

Board Certifications

American Board Of Internal Medicine

Fellowships

Western Pennsylvania Hospital

Hospital Affiliations

Magee Womens Hospital Of Upmc Health System
Upmc Northwest
Upmc Hamot

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center - Erie
2500 West 12th Street, Erie, PA 16505

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 20, 2026
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma
Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: June 27, 2025
Intervention Type: Device
Study Phase: Not Applicable
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Enrollment Status: Terminated
Publish Date: October 11, 2023
Intervention Type: Radiation, Drug
Study Phase: Phase 2
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cetuximab, Docetaxel
Study Phase: Phase 2
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
View 9 Less Clinical Trials

42 Total Publications

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).
Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).
Journal: The oncologist
Published: January 27, 2026
Similar Doctors
Expertise in
48
conditions
Dr. Jan M. Rothman
Hematology Oncology
Expertise in
48
conditions
Dr. Jan M. Rothman
Hematology Oncology
Referral may be required
Before you request

UPMC Hillman Cancer Center - Erie

2500 West 12th Street, 
Erie, PA 
 (0.1 miles away)
814-836-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jan M. Rothman, MD, is a medical oncologist and treats all medical oncology and hematology cases. Dr. Rothman is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Lung Cancer, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Bone Marrow Aspiration. Dr. Rothman is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Rothman is currently accepting new patients.

Expertise in
52
conditions
Dr. David J. Seastone
Hematology Oncology
Expertise in
52
conditions
Dr. David J. Seastone
Hematology Oncology
Referral may be required
Before you request

UPMC Hillman Cancer Center - Erie

2500 West 12th Street, 
Erie, PA 
 (0.1 miles away)
814-836-2600
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David James Seastone, DO, PhD, is a medical oncologist and treats all medical oncology and hematology cases. Dr. Seastone is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Seastone is board certified in American Board Of Internal Medicine. Dr. Seastone is currently accepting new patients.

Expertise in
24
conditions
Dr. Zulfiqar Hussain
Hematology Oncology
Expertise in
24
conditions
Dr. Zulfiqar Hussain
Hematology Oncology
Referral may be required
Before you request

UPMC Hillman Cancer Center - Erie

2500 West 12th Street, 
Erie, PA 
 (0.1 miles away)
814-836-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Zulfiqar Hussain, MD, FACP is a medical oncologist and treats all hematology cases and solid malignancies. Dr. Hussain is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Thrombocytopenia. Dr. Hussain is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Hussain is currently accepting new patients.

Frequently Asked Questions about Dr. James P. Ohr

How do I make an appointment with Dr. James P. Ohr?

You can book an appointment with Dr. James P. Ohr by calling their office at 814-836-2600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James P. Ohr a top-rated expert for Throat Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James P. Ohr is classified as an Distinguished expert for Throat Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James P. Ohr specialize in?

While Dr. James P. Ohr is a Hematology Oncology, they have specific expertise in Throat Cancer, Laryngeal Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. James P. Ohr participate in research or clinical trials?

Yes. Dr. James P. Ohr has published 42 articles and abstracts on conditions like Throat Cancer. You can view a list of Dr. James P. Ohr's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James P. Ohr accept my insurance?

Dr. James P. Ohr accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 814-836-2600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ohr's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 116 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile